

Pursuant to the provisions of article 228 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("Grifols") hereby informs about the following

RELEVANT EVENT

Grifols has subscribed a capital increase in the amount of USD 50M in the US company Singulex, Inc. ("Singulex"). As a result, Grifols will hold a 20% common stock interest in Singulex on a fully diluted basis at a pre-money valuation of USD 200M. Grifols will be entitled to appoint a director to serve on the board of directors of Singulex.

In addition to this, Singulex has granted Grifols an exclusive worldwide license for the use and sale of Singulex' technology for the blood donor and plasma screening to further ensure the safety of blood and plasma products.

Singulex is a US company, with headquarters based in Alameda, California, and is the developer of the Single Molecule Counting (SMCTM) technology for clinical diagnostic and scientific discovery. This technology enables to detect biomarkers of diseases that were previously undetectable. Singulex is developing a fully-automated *in vitro* diagnostics system that will bring its technology to hospital and reference laboratories worldwide.

Singulex provides clinical laboratory testing services to enhance the early detection of cardiac and vascular disorders and sells immunoassay tests and services. This acquisition will reinforce Grifols' diagnostic division.

In Barcelona, on 17th May 2016

Nuria Martín Barnés
Secretary to the Board of Directors